HOME > TOP STORIES
TOP STORIES
-
REGULATORY Sakigake Status Should Not Be Granted to Novartis Products until It Takes Prevention Measures for Approval Delay: Pharma Bureau Chief
September 8, 2020
-
ORGANIZATION JPMA to Commit to Growth of Research-Driven Pharma Industry, R&D of COVID-19 Drugs, Vaccines: Director General
September 7, 2020
-
BUSINESS Blackstone Setting Sights on IPO of Takeda Consumer Healthcare Within 5-10 Years
September 4, 2020
-
REGULATORY Will Temporary Measures in R&D Tax Credit System Be Extended? Enthusiasm for R&D Investment Could Determine Outcome
September 3, 2020
-
BUSINESS Mitsubishi Tanabe’s HIF-PH Inhibitor Hit by Shortage Days after Launch on Better-than-Expected Demand
September 2, 2020
-
BUSINESS Japan Sees Showdown of 3 HIF-PH Inhibitors as 2 New Drugs Enter Market
September 1, 2020
-
REGULATORY Japan in Talks to Secure 40 Million-Plus Doses of Moderna Vaccine via Takeda: Minister
August 31, 2020
-
BUSINESS Nichi-Iko to Revamp Quality Control System after Massive Recalls by Leveraging Teva Takeda Plant
August 28, 2020
-
REGULATORY MHLW to Accept Sakigake Applications All Year Long under Amended PMD Law
August 27, 2020
-
BUSINESS 2 More HIF-PH Inhibitors, Enerzair, Enspryng and More Now Available in Japan
August 27, 2020
-
BUSINESS As Entresto Hits Japan Market, Novartis Poised to Tap All Channels to Push Global Blockbuster
August 26, 2020
-
COMMENTARY COVID-19 Pandemic to Test True Value of MHLW’s Officers with Medical/Pharma Backgrounds
August 26, 2020
-
BUSINESS Drug Makers Taking Mixed Disclosure Policies for Coronavirus Infections
August 25, 2020
-
BUSINESS Takeda to Sell Japan OTC Biz to Blackstone, Weber Says It’s the Right Choice
August 25, 2020
-
BUSINESS Japan Drug Makers’ Q1 Profit Surges on Voluntary Bans on Doctor Calls: Jiho Tally
August 24, 2020
-
REGULATORY Japan to Look at H1N1 Flu Rules to Consider Indemnity for COVID-19 Vaccine Makers
August 24, 2020
-
REGULATORY Japan Plans to Provide Indemnity to Coronavirus Vaccine Suppliers
August 21, 2020
-
BUSINESS Boehringer’s Ofev Already Hits Japan Peak Sales Outlook, Momentum Likely to Continue with New Indications
August 20, 2020
-
REGULATORY Entresto, Enerzair, 2 More HIF-PH Inhibitors OK'ed for Listing on August 26
August 19, 2020
-
BUSINESS Novo to Skip August Listing for 1st Oral GLP Agent Rybelsus
August 18, 2020
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
